PECAM1 and type 2 diabetes mellitus: The AngioSafe Type 2 Diabetes Study evaluated whether GLP-1 receptor agonists could be associated with the development of DR in T2DM patients, detecting no changes in the number of hematopoietic progenitor cells (HPCs: CD34+CD45dim) and HPCs cells with angiogenic activity (CD34+CD45dimCD133+CD31+) after the 4-weeks treatment with liraglutide [192].